Immuneering Leads The Pack Of 3 US Penny Stocks To Consider

In This Article:

As the S&P 500 nears record highs, fueled by a surge in AI stocks and robust earnings reports, investors are keenly observing opportunities across various market segments. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

QuantaSing Group (NasdaqGM:QSG)

$3.08

$110.92M

★★★★★★

BAB (OTCPK:BABB)

$0.87505

$6.41M

★★★★★★

Kiora Pharmaceuticals (NasdaqCM:KPRX)

$3.87

$12M

★★★★★★

Inter & Co (NasdaqGS:INTR)

$4.97

$2.09B

★★★★☆☆

ZTEST Electronics (OTCPK:ZTST.F)

$0.2896

$11.03M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$2.925

$89.18M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

BTCS (NasdaqCM:BTCS)

$3.12

$59.16M

★★★★★★

Smith Micro Software (NasdaqCM:SMSI)

$1.28

$22.17M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.9272

$82.51M

★★★★★☆

Click here to see the full list of 709 stocks from our US Penny Stocks screener.

We'll examine a selection from our screener results.

Immuneering

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Immuneering Corporation is a clinical-stage oncology company focused on developing medicines for broad populations of cancer patients, with a market cap of $65.83 million.

Operations: Immuneering Corporation does not report any revenue segments as it is a clinical-stage oncology company.

Market Cap: $65.83M

Immuneering Corporation, with a market cap of US$65.83 million, remains pre-revenue as it advances its clinical-stage oncology endeavors. The company is debt-free and has experienced management and board teams but faces challenges with less than a year of cash runway. Recent updates from Phase 2a trials showed promising results in pancreatic cancer treatments, achieving higher response rates compared to standard therapies while maintaining tolerability. Despite these advancements, Immuneering's earnings are forecast to decline over the next three years, and it remains unprofitable without significant revenue streams expected in the near term.

NasdaqGM:IMRX Debt to Equity History and Analysis as at Jan 2025
NasdaqGM:IMRX Debt to Equity History and Analysis as at Jan 2025

Pixelworks

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Pixelworks, Inc. develops and markets semiconductor and software solutions for mobile, home and enterprise, and cinema markets across the United States, Japan, China, Taiwan, Korea, and Europe with a market cap of $50.07 million.